Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results

Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies

Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections

Avid Bioservices Expands Capabilities With Installation of Innovative Thermo Scientific HyClone Single-Use Bioreactor Systems

Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008

Avid Bioservices to Serve as Contract Manufacturer for Catalyst Biosciences' Novel Human Coagulation Factor Clinical Candidate

Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQ's Minimum Bid Price Rule

Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial